Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVERS.L Regulatory News (VERS)

  • There is currently no data for VERS

Depository Interest Programme

28 Aug 2015 09:34

RNS Number : 4311X
Verseon Corporation
28 August 2015
 



Verseon Corporation

("Verseon" or the "Company")

 

Depository Interest Programme

 

Verseon Corporation (AIM: VSN) announces that it has introduced a Depository Interest programme ("DI Programme") in respect of its common shares ("Common Shares") with the Company's registrar, Computershare Investor Services PLC ("Computershare"), to enable the Common Shares to be settled electronically via CREST.

 

It is expected that the DI Programme will be effective from 1 September 2015. The Company's existing ISIN (USU9221J1098) and ticker (VSN) will remain the same and, from 1 September 2015, will represent the depository interests ("Verseon Depository Interests"). The introduction of the DI Programme will ensure that Verseon will be in compliance with the AIM Rules and EU regulations which require securities traded on AIM to be capable of electronic settlement with effect from 1 September 2015. The benefit of the DI Programme is that the Verseon Depository Interests can be held and transferred through CREST, which should shorten the settlement process significantly. This will potentially widen the pool of investors that can hold the securities by making them available to investors who are unable to hold securities which are not eligible for electronic settlement.

 

Shareholders should note that from 1 September 2015, holdings of certificated Common Shares will be eligible for dematerialisation into Verseon Depository Interests which shall be capable of electronic settlement in CREST. Shareholders are encouraged to contact their broker or Computershare directly on +44 (0)370 707 4040 for further details on the DI Programme and how to dematerialise their holding of Common Shares.

 

As described in more detail in the Company's admission document published on 1 May 2015, which is available on the Company's website, the Company's securities are subject to certain restrictions on transfers under Regulation S of the United States Securities Act of 1933, as amended. This restriction, which appears as a legend on the certificated Common Shares, shall continue to apply to the Verseon Depository Interests. The distribution compliance period in respect of the Common Shares issued pursuant to the admission document expires on 7 May 2016 and the Company will make a further announcement closer to that date with details of an unrestricted depository interest line of security which would have a different ticker and ISIN, into which eligible Verseon Depository Interests or Common Shares may be transferred or placed.

 

Any enquiries should be directed to Computershare on +44 (0)370 707 4040.

 

 

Contact details:

 

Computershare Investor Services (Jersey)

+44 (0)370 707 4040

 

Verseon Corporation

+1 (510) 225 9000

Adityo Prakash, Chief Executive Officer

 

Cenkos Securities (NOMAD and Broker)

+44 (0) 20 7397 8900

Christopher Golden / Mark Connelly

 

FTI Consulting (PR Advisers)

+44 (0) 20 3727 1000

Simon Conway / Robert Winder / Matthew Moss

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCPGUPWRUPAURR
Date   Source Headline
24th Oct 20187:00 amRNSAnnouncement of 2018 Annual General Meeting
11th Oct 20187:00 amRNSBlockchain agreement with Neuseren
1st Oct 20188:59 amRNSAdditional Listing & Total Voting Rights
18th Sep 20187:00 amRNSVerseon unveils new blockchain technology
13th Sep 20187:00 amRNSVerseon commences anticoagulant phase I trial
31st Aug 20187:00 amRNSAdditional Listing & Total Voting Rights
16th Aug 20187:00 amRNSChange of Adviser
8th Aug 20187:00 amRNSInterim Results
18th Jul 20187:00 amRNSVerseon submits phase I protocol for VE-1902
6th Jul 20187:00 amRNSAdditional Listing & Total Voting Rights
2nd Jul 20187:00 amRNSAdditional Listing & Total Voting Rights
25th Jun 20187:00 amRNSFinal Results
14th Jun 20187:00 amRNSVerseon preparing for anticoagulant phase I trial
13th Jun 20187:03 amRNSVerseon closes US$ 22.7M mortgage
12th Jun 20187:00 amRNSAdditional Listing & Total Voting Rights
7th Jun 20187:00 amRNSVerseon presents anticoagulants at BIO 2018
2nd May 20187:00 amRNSVerseon presents DME efficacy data at ARVO 2018
18th Apr 20187:00 amRNSVerseon presents anticancer agents at AACR 2018
3rd Apr 20187:00 amRNSAdditional Listing & Total Voting Rights
5th Mar 20187:00 amRNSAdditional Listing & Total Voting Rights
10th Jan 20187:00 amRNSVerseon presents HAE program at Biotech Showcase
2nd Jan 20187:00 amRNSAdditional Listing & Total Voting Rights
15th Nov 20177:00 amRNSVerseon presents second anticoagulant candidate
14th Nov 20177:00 amRNSAdditional Listing & Total Voting Rights
8th Nov 20177:00 amRNSVerseon presents anticancer agents at BIO-Europe
8th Nov 20177:00 amRNSAdditional Listing & Total Voting Rights
20th Oct 20177:00 amRNSResult of Special Meeting & Board Appointment
2nd Oct 20177:00 amRNSVerseon presents new DME efficacy results
25th Sep 20177:00 amRNSInterim Results
25th Sep 20177:00 amRNSSpecial Shareholder Meeting & Change of Directors
22nd Sep 20177:00 amRNSVerseon closes PACE financing for its new facility
7th Aug 20177:00 amRNSAdditional Listing and Total Voting Rights
26th Jun 20177:00 amRNSVerseon presents data on DME program at BIO 2017
12th Jun 20177:00 amRNSVerseon to present drug programs at BIO 2017
6th Jun 20178:15 amRNSTransaction in Own Shares and Total Voting Rights
2nd May 20177:00 amRNSAdditional Listing & Total Voting Rights
26th Apr 20177:00 amRNSTR-1 Notification of Major Interest in Shares
26th Apr 20177:00 amRNSResult of 2017 Annual General Meeting
3rd Apr 20177:00 amRNSAnnouncement of 2017 Annual General Meeting
30th Mar 20177:00 amRNSVerseon to present anticoagulants at ACS 2017
20th Mar 20177:00 amRNSBIO-Europe Spring: Verseon presents anticoagulants
13th Mar 20177:00 amRNSFinal Results
30th Jan 20177:00 amRNSAdditional Listing & Total Voting Rights
4th Jan 20177:00 amRNSVerseon granted US patents for its inhibitors
6th Dec 20167:00 amRNSLower bleeding risk of Verseon anticoagulants
23rd Nov 20167:03 amRNSVerseon anticoagulants preserve platelet function
16th Nov 20167:00 amRNSAdditional Listing & Total Voting Rights
14th Nov 20167:00 amRNSNew anticoagulant data to be presented at AHA 2016
7th Nov 20167:00 amRNSAppointment of Corporate Brokers
31st Oct 20167:00 amRNSAdditional Listing & Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.